Prostate Cancer Imaging Agents – Is There a Difference?
December 10, 2024 | 12:00 pm ET
Organized as part of the SNMMI/ACNM "Hot Topics" Webinar Series
Organizer:
Katherine Zukotynski, BASc, MD, PhD, P.Eng; Gary Ulaner, MD, PhD, FACNM; Twyla Bartel, DO, MBA, FACNM
Moderator: Sanchay Jain, MBBS, MD
Speaker: Wolfgang Weber, MD
Course Summary:
This presentation will give an overview of PSMA ligands in clinical use for PET/CT and PET/MR imaging of prostate cancer.
Course Objectives:
- Examine the three FDA approved PSMA ligands and their clinical indications.
- Discuss differences in the biodistribution between these ligands.
- Identify common pitfalls of the ligands.
CE Information:
CE Credit applications for physicians, pharmacists, physicists and technologists are pending. Check back for updates regarding CE Credit status.